Rare Endocrine Disease Treatment Market to Exceed US$ 12,000 Mn in 2026
The global rare endocrine disease treatment market will exhibit a moderate expansion in the period between 2017 and 2026, according to a new report of Persistence Market Research (PMR). Treatment of rare endocrine diseases across the globe are foreseen to close in on roughly US$ 12,000 Mn revenues by 2026-end.
Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/22579
endoVL Enabling Researchers to Collaborate on Rare Endocrine Disease Treatment Developments
A number of rare endocrine conditions that include disorders of sex development and adrenal tumors have made life of patients affected with these diseases miserable, thereby gaining attraction of researchers for developing treatment options. However researchers face challenges regarding collection of efficient patient data, which offer clinical trials with a powerful statistical support.
endoVL, by utilizing world-class research infrastructure of Australia, offers researchers with a secure online access to analytical tools & extensive data sets, so as to enable them to work together for developing effective treatment measures for rare endocrine diseases. With over 25 remarkable clinical trials on rare endocrine disease treatment drugs that are currently being run in endoVL, several research groups from around the world are working in collaboration to realize treatment options for these diseases.
North America to Remain Largest Market for Rare Endocrine Disease Treatment
Prevalence of Beckwith-Wiedemann Syndrome (BWS) is as significant as 1/10,000 live births. Rare endocrine tumors, such as neoplasia, have been associated with adults suffering from. Occurrence of BWS in the adult population has gained a slight uptick in North America, according to the NIH. This has further triggered development and supply of treatment measures for this rare disease, underpinned by the region’s robust economic and resource vigour. PMR’s report estimates North America to remain the largest as well as the fastest-growing market for rare endocrine disease treatment.
Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative regions for growth of the rare endocrine disease treatment market. Revenues from the market in these two regions will register a moderate CAGR, and are collectively forecast to surpass those from North America by 2026-end.
Acromegaly to Remain Most Prevalent Indication among Rare Endocrine Diseases
Acromegaly will continue to be the most prevalent indication among rare endocrine diseases, with revenues from treatment of this indication estimated to account for bulk share of the market during the period of forecast. Despite high rarity of acromegaly, progression of the disease has been insidious. Researchers view earlier diagnosis and increased clinical vigilance to make real difference in lives of patients with acromegaly. Central diabetes insipidus will also prevail as a significant indication of rare endocrine disease, with revenues from treatment of this indication envisaged to surpass US$ 3,000 Mn by 2026-end.
Request Report Multiple Chapter @ https://www.persistencemarketresearch.com/multiple-chapter/22579
Biologics will continue to be the preferred drug type for treatment of rare endocrine diseases. Although oral mode of administration of drugs related to rare endocrine diseases are witnessing a relatively faster penetration, revenues from their injectable counterparts are expected to remain larger throughout the forecast period. Based on distribution channel, hospital pharmacies will continue to lead the market, in terms of revenues.
Get full report now @ https://www.persistencemarketresearch.com/checkout/22579
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rare Endocrine Disease Treatment Market to Exceed US$ 12,000 Mn in 2026 here
News-ID: 1043345 • Views: 134
More Releases from Persistence Market Research pvt ltd
Osteoarthritis Treatment Market Analysis By 2025 | Top Key Players are Johnson & …
Persistence Market Research (PMR) has published a new research report on the osteoarthritis treatment market titled “Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025).” An alarming rise in the number of osteoarthritis cases is the result of a growing geriatric population worldwide. In order to cater to the needs of the rapidly increasing geriatric population as well as the female population – given that osteoarthritis prevails mostly among
Soft Tissue Repair Market Opportunity By 2024 | Top Key Players are Baxter, B. B …
Soft tissue repair is a process of replacement of destroyed or injured tissue by healthy tissue. One of the key factors driving the market is the rise in a number of accidents and accidental injuries. This is leading to the soft tissue injuries in ligaments, muscle, and tendons. Soft tissue injuries are being treated with soft tissue fixation devices and scaffolds. Increasing number of sports injuries is also driving the
Biosensor Market Forecast By 2020 | Top Key Players are Abbott Laboratories, Inc …
According to a new market report published by Persistence Market Research “Global Market Study on Biosensor: Asia-Pacific to Witness Highest Growth by 2020,” the global biosensor market was valued at USD 12,963.6 million in 2014 and is expected to grow at a CAGR of 9.7% from 2014 to 2020, to reach an estimated value of USD 22,551.2 million in 2020. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/3589 Globally, the
Growing Usage in Non-medical Sectors to Create Promising Prospects for Medical & …
Persistence Market Research has estimated the global market for medical & industrial gloves at US$ 12,868.6 Mn by the end of 2026, exhibiting robust expansion at a CAGR of 7.9% over 2018–2026. According to the latest market outlook released by the company, the global Medical & Industrial Gloves Market holds promising growth prospects over the next eight years. The market will benefit from multiple innovations through intense research and
More Releases for Endocrine
Endocrine testing market is driven by the increasing incidences of endocrine dis …
The endocrine system comprises of the endocrine glands such as the pituitary, thyroid, pancreas, adrenal, etc. These glands secrete hormones that regulate the body’s metabolism, growth, sexual development, and function. Endocrine tests help in assessing the normal functioning of the endocrine gland by checking the hormone levels. Get a sample report @ https://www.alliedmarketresearch.com/request-toc-and-sample/306?utm_source=openpr&utm_medium=Niranjan The tests detect the imbalance in hormonal levels. The various tests, their advantages, and uses are described
Endocrine Peptides Test Market to Witness Robust Expansion by 2023
New report published by Global Info Research which offers insights on the global Endocrine Peptides Test market. Endocrine peptide test is used for the measurement of the level of c-peptide present in the blood. C-peptide and insulin are usually found in equivalent amounts. Click to view the full report TOC, figure and tables： https://www.globalinforesearch.com/global-endocrine-peptides-test-market_p87116.html Global Endocrine Peptides Test Market: Forecast by Type / Application / Region The worldwide market
Endocrine Testing Market - Size, Share, 2026
Endocrine testing procedure consist of measuring concentration of endocrinal hormones in blood or urine. These hormones are precise marker for presence of endocrinal disease such as hypo/hyperthyroidism, infertility etc. Various endocrine glands present in body include pituitary glands, thyroid glands, hypothalamus, pancreas, and adrenal glands. Any imbalance in the hormones secreted by this glands leads to certain disorder therefore they are important marker to diagnose certain condition. Get PDF Research Brochure
Endocrine Testing Market Scope and Opportunities Analysis 2015 – 2023
Endocrine testing refers to a group of tests performed to assess the overall function of the patient’s endocrine system. The release of hormones is linked to a variety of diseases, which makes them a solid indicator to reveal the nature and extent of diseases. The rising awareness about the solid connection between hormones and diseases has led to steady growth of the global endocrine testing market in the recent past.
Endocrine Testing Market: Research Methodology
The global endocrine testing market features a fairly oligopolistic structure with the top five players occupying a combined market share of 90.0% in 2014, finds Transparency Market Research (TMR). These companies are Siemens Healthineers, DiaSorin, Agilent Technologies, Abbott Laboratories, and F. Hoffmann-La Roche AG. Among the leading players, Roche emerged as the dominant players in 2014. The leading companies are developing advanced lab automation systems, next-generation sequencing platforms, endocrine test
Endocrine Testing Market Studies Research Report 2023
Global Endocrine Testing Market: Snapshot Endocrine testing refers to a group of tests performed to assess the overall function of the patient’s endocrine system. The release of hormones is linked to a variety of diseases, which makes them a solid indicator to reveal the nature and extent of diseases. The rising awareness about the solid connection between hormones and diseases has led to steady growth of the global endocrine testing market